All In Biotech

Drug Trial Radar · NCT05189210

GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the Safety and Efficacy of GV1001 Administered Subcutaneously for the Treatment of Mild to Moderate AD

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 199 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

199

Actual

Start

Oct 5, 2022

Primary completion

Apr 3, 2025

Study completion Apr 16, 2025

Sponsor

Lead sponsor
GemVax & KaelIndustry
Sponsor type
Industry
First posted
Jan 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered subcutaneously as a treatment for mild to moderate Alzheimer's disease (AD). Studies using in vivo and in vitro AD models have shown that GV1001 inhibits neurotoxicity, apoptosis, and the production of reactive oxygen species induced by amyloid beta (Aβ) in neural stem cells by mimicking the extra-telomeric functions of human telomerase reverse transcriptase (hTERT). In nonclinical studies, using both mild (early stage) and severe (late stage) AD mouse models, GV1001 was shown to improve cognitive function and memory, as well as significantly reduce the amount of Aβ and tau proteins. The multifunctional effect of GV1001 makes it a promising therapeutic option for the treatment for AD. In a completed Phase 2 study conducted in Korea, GV1001 showed significant improvement in change from baseline of Severe Impairment Battery score at Week 24 and demonstrated a clinically acceptable safety profile in patients with moderate to severe AD.

Conditions

  • Mild to Moderate Alzheimer's Disease

Interventions

  • GV1001 PlaceboDrug

    0.9% normal saline

  • GV1001 0.56mgDrug

    Lyophilized peptide from hTERT

  • GV1001 1.12mgDrug

    Lyophilized peptide from hTERT

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in ADAS-Cog11 score at Week 52Time frame: Baseline, Week 12, Week 26, Week 38, and Week 52

Locations

35 sites in 8 countries. Site status is shown where the registry gives one.

  • First Choice Neurology - Aventura Neurologic Associates

    Adventura, Florida

  • Finlay Medical Research Corporation - Greenacres

    Greenacres City, Florida

  • Outpatient Psy Care

    Miami, Florida

  • Finlay Medical Research Corporation - Miami Dade

    Miami, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • Palm Beach Neurological Center

    Palm Beach Gardens, Florida

  • Neurostudies - Port Charlotte

    Port Charlotte, Florida

  • Palm Beach Neurology and Premiere Research Institute

    West Palm Beach, Florida

  • Accel Research Sites (ARS) - NeuroStudies

    Decatur, Georgia

  • Global Medical Institutes - Princeton Medical Institute

    Princeton, New Jersey

  • Flourish Research - Alzheimer's Memory Center/AMC Research, LLC

    Charlotte, North Carolina

  • Neurology Clinic - Cordova

    Cordova, Tennessee

  • Terveystalo Oulu

    Oulu, Finland

  • Hôpital La Grave

    Toulouse, Midi-Pyrenees, France

  • Hôpital Pierre Wertheimer

    Bron, Rhône, France

  • Casa di Cura iGEA SpA c/o Casa di Cura Privata del Policlinico

    Milan, Italy

  • Brain Research Centre - Den Bosch

    Amsterdam, Netherlands

  • Brain Research Center - Amsterdam

    Amsterdam, North Holland, Netherlands

  • Brain Research Center - Zwolle

    Zwolle, Overijssel, Netherlands

  • Centrum Medyczne Neuromed - Ośrodek Badań Klinicznych

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Wroctawskie Centrum Alzheimerowskie (WCA)

    Wroclaw, Lower Silesian Voivodeship, Poland

  • Galen Clinic

    Lublin, Lublin Voivodeship, Poland

  • Centrum Medyczne Neuroprotect

    Warsaw, Masovian Voivodeship, Poland

  • Niepubliczny Zakład Opieki Zdrowotnej NOVO-MED

    Katowice, Silesian Voivodeship, Poland

  • Clinhouse Centrum Medyczne

    Zabrze, Silesian Voivodeship, Poland

  • Unidade Local de Saúde de Braga, E. P. E (Hospital de Braga)

    Braga, Portugal

  • Unidade Local de Saúde de Santa Maria, E. P. E. - Hospital de Santa Maria

    Lisbon, Lisbon District, Portugal

  • Hospital Pedro Hispano

    Senhora da Hora, Porto District, Portugal

  • Hospital Universitari Vall d'Hebrón

    Barcelona, Spain

  • Hospital Clinic de Barcelona

    Barcelona, Spain

  • Fundacio ACE

    Barcelona, Spain

  • Hospital Victoria Eugenia

    Seville, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Hospital Universitari i Politècnic La Fe

    Valencia, Spain

  • Hospital Universitario Quirónsalud Madrid

    Pozuelo de Alarcón, Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.